Drug License
-
MS-20 is a mixture of soybean fermentation metabolites which is produced in strictly controlled fermenter and with carefully chosen microorganisms that mimics the human intestinal environment.
-
The manufacturing and R&D procedures of Chemo young follow the international regulations.
-
MS-20 can promote the growth of probiotics and act as an immunomodulator to improve immunity and inhibit tumor growth.
-
MS-20 is the first and the only oral new drug for ameliorating fatigue and appetite loss in patients receiving chemotherapy and thus improves the quality of life.
-
MS-20 is estimated to be approximately NT$4.5 billion in the Taiwan market, with an annual increase of 90,000 cancer patients. The number of cancer patients worldwide will reach 1.4 million, and medical needs will exceed $20 billion annually.
-
Herbiron in accordance with the concept of Chinese and Western cultures, is composed of Chinese herbal medicine and well-known study Ferrous Bisglycinate.
-
Ferrous Bisglycinate is easily absorbed by the body, can increase iron utilization, more than other iron supplements.
-
Herbiron was approved as the new drug by Ministry of Health and Welfare (MOHW) in 2013.
-
Herbiron's clinical efficacy was confirmed in Phase III trials to significantly improve symptoms of iron deficiency anemia in women before menopause and relieved Dysmenorrhea.
-
The safety of Herbiron was demonstrated in Phase III trials, and the incidence of gastrointestinal side effects was significantly reduced in Herbiron-treated subjects compared to subjects treated with ferrous sulfate.
